首页> 美国卫生研究院文献>Emerging Microbes Infections >Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia
【2h】

Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia

机译:SARS-CoV-2感染潜在发病机制的假说–病毒性肺炎患者免疫变化的综述

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with droplets and contact as the main means of transmission. Since the first case appeared in Wuhan, China, in December 2019, the outbreak has gradually spread nationwide. Up to now, according to official data released by the Chinese health commission, the number of newly diagnosed patients has been declining, and the epidemic is gradually being controlled. Although most patients have mild symptoms and good prognosis after infection, some patients developed severe and die from multiple organ complications. The pathogenesis of SARS-CoV-2 infection in humans remains unclear. Immune function is a strong defense against invasive pathogens and there is currently no specific antiviral drug against the virus. This article reviews the immunological changes of coronaviruses like SARS, MERS and other viral pneumonia similar to SARS-CoV-2. Combined with the published literature, the potential pathogenesis of COVID-19 is inferred, and the treatment recommendations for giving high-doses intravenous immunoglobulin and low-molecular-weight heparin anticoagulant therapy to severe type patients are proposed.
机译:冠状病毒病2019(COVID-19)是由严重急性呼吸系统综合症冠状病毒2(SARS-CoV-2)引起的一种传染病,其以飞沫和接触为主要传播手段。自从第一例病例于2019年12月在中国武汉出现以来,疫情已逐步向全国蔓延。到目前为止,根据中国卫生委员会发布的官方数据,新诊断的患者数量一直在下降,该病正在逐步得到控制。尽管大多数患者在感染后症状较轻且预后良好,但仍有一些患者病情严重且死于多器官系统并发症。人类SARS-CoV-2感染的发病机制仍不清楚。免疫功能对入侵的病原体具有很强的防御作用,目前尚无针对该病毒的抗病毒药物。本文回顾了冠状病毒如SARS,MERS和其他与SARS-CoV-2类似的病毒性肺炎的免疫学变化。结合已发表的文献,推测COVID-19的潜在发病机理,并提出了对重症型患者进行大剂量静脉内免疫球蛋白和低分子量肝素抗凝治疗的治疗建议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号